Vascular and Metabolic Consequences of Adopting a Westernized Lifestyle
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- University of Missouri
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women who regularly engage in >10,000 steps per day
- Age 18-45 years
- Body mass index < 30 kg/m2
- No history of chronic disease
Exclusion Criteria:
- Known cardiovascular disease including hypertension, heart failure, coronary artery disease, and stroke
- Renal or hepatic diseases
- Active cancer
- Autoimmune diseases
- Current use of immunosuppressant therapy
- Excessive alcohol consumption (> 14 drinks/week for men and >7 drinks/week for women)
- Current tobacco use
- Current pregnancy
- Diagnosis of type 2 diabetes
- Regular consumption of >2 non-diet sodas/day
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Fructose and physical inactivity
Subjects will consume 6 cans of soda per day and restrict their physical activity.
|
Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Insulin-stimulated leg blood flow
Time Frame: this will be assessed at baseline and at the final visit (10 days)
|
Subjects will be instrumented with EKG for contrast-enhanced ultrasound (CEU) measurements.
We will perform a hyperinsulinemic euglycemic clamp to evaluate microvascular perfusion of skeletal muscle via CEU.
Insulin will be infused at a constant rate to mimic postprandial insulin concentrations and glucose maintained at fasting values via a variable 20% dextrose infusion.
At baseline and in the steady state phase of the insulin clamp, we will assess microvascular perfusion in the vastus lateralis muscle using CEU (IE-33, Philips Ultrasound), via infusion of perflutren lipid microspheres.
Microvascular perfusion will be assessed as an A-value.
A is the video intensity plateau after complete replenishment reflecting relative microvascular blood volume (MBV).
|
this will be assessed at baseline and at the final visit (10 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Brachial artery flow mediated dilation (FMD)
Time Frame: this will be assessed at baseline and at the final visit (10 days)
|
Brachial artery FMD will be assessed at baseline and at 10 days.
FMD is a measurement of conduit artery endothelial function.
FMD is assessed immediately after each PWV measurement.
Shear rate AUC until peak diameter is calculated as stimulus for FMD and used in covariate analysis.
All measurements will be performed by the same technician.
|
this will be assessed at baseline and at the final visit (10 days)
|
|
Change in carotid femoral pulse wave velocity (cfPWV)
Time Frame: this will be assessed at baseline and at the final visit (10 days)
|
It is the gold standard non-invasive index of arterial stiffness.
Transit time between carotid and femoral pressure waves is calculated using the foot-to-foot method.
cfPWV is calculated as distance traveled by the pulse wave (i.e., femoral location-sternal notch minus sternal notch-carotid location) divided by pulse transit time.
All the measurements will be done by the same technician
|
this will be assessed at baseline and at the final visit (10 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2012869
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.